Suppr超能文献

心血管药物和二甲双胍使用者开始使用抗抑郁药的风险。来自挪威特隆赫姆健康研究(HUNT)和挪威处方数据库(NorPD)的发现:来自挪威特隆赫姆健康研究(HUNT)和挪威处方数据库(NorPD)的发现。

Risk of antidepressant initiation among users of cardiovascular agents and metformin. Findings from the Trøndelag Health Study (HUNT) and Norwegian Prescription Database (NorPD), Norway: Findings from the Trøndelag Health Study (HUNT) and Norwegian Prescription Database (NorPD), Norway.

机构信息

Faculty of Nursing and Health Sciences, Nord University, Levanger, Norway.

Department of Public Health and Nursing, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, NTNU, Trondheim, Norway.

出版信息

Pharmacol Res Perspect. 2023 Apr;11(2):e01078. doi: 10.1002/prp2.1078.

Abstract

Cardiovascular disease and diabetes are risk factors for depression, yet the relationship between the drug treatments for these diseases and the risk of antidepressant initiation remains unclear. This study aimed to examine possible associations between the use of angiotensin II receptor blockers (ARBs), angiotensin-converting enzyme inhibitors (ACEI), acetylsalicylic acid (ASA), beta-blockers (BB), calcium channel blockers (CCB), diuretics, or metformin and risk of antidepressant initiation. The Trøndelag Health Study (HUNT3), Norway, was linked to the Norwegian Prescription Database (NorPD). Participants with no prescriptions of cardiovascular agents, metformin, or antidepressants for at least 6 months before HUNT3 (baseline) were eligible and followed for 10 years. The exposure was the use of cardiovascular agents or metformin, defined as mono- or polytherapy from baseline to end of follow-up. The outcome was the initiation of antidepressant use, indicated by the first drug dispensation during the study period and expressed as hazard ratios (HRs) with 95% confidence intervals (CI). Among 20 227 adults aged 40-70 years at baseline, we observed different associations between cardiovascular agents or metformin and the risk of antidepressant initiation. ARBs or CCB monotherapy was associated with a lower risk of initiating antidepressant use (HR 0.70; 95%CI 0.56-0.88 and HR 0.81; 95%CI 0.61-1.06, respectively) compared to no use of any drugs included in the study (reference). Reduced risk of antidepressant initiation was among ASA or statin polytherapy users, whereas there was a small increased risk among participants on ASA monotherapy. In contrast, there was no statistical evidence of associations between ACEI, BB, diuretics, or metformin and increased or decreased risk of antidepressant initiation. Our mixed findings indicate the possibility that some cardiovascular agents may be associated with a reduced risk of initiating antidepressant use while others may not. However, bias due to the limitations of the study design is possible.

摘要

心血管疾病和糖尿病是抑郁症的危险因素,但这些疾病的药物治疗与抗抑郁药起始风险之间的关系尚不清楚。本研究旨在探讨血管紧张素 II 受体阻滞剂(ARB)、血管紧张素转换酶抑制剂(ACEI)、乙酰水杨酸(ASA)、β受体阻滞剂(BB)、钙通道阻滞剂(CCB)、利尿剂或二甲双胍的使用与抗抑郁药起始风险之间的可能关联。挪威特隆赫姆健康研究(HUNT3)与挪威处方数据库(NorPD)相关联。在 HUNT3(基线)前至少 6 个月没有心血管药物、二甲双胍或抗抑郁药处方的参与者符合条件,并随访 10 年。暴露因素是心血管药物或二甲双胍的使用,定义为从基线到随访结束时的单药或多药治疗。结局是抗抑郁药使用的起始,由研究期间的首次药物配给表示,并以危险比(HR)和 95%置信区间(CI)表示。在基线时年龄为 40-70 岁的 20227 名成年人中,我们观察到心血管药物或二甲双胍与抗抑郁药起始风险之间存在不同的关联。与不使用研究中包含的任何药物(参照)相比,ARB 或 CCB 单药治疗与抗抑郁药起始使用的风险降低相关(HR 0.70;95%CI 0.56-0.88 和 HR 0.81;95%CI 0.61-1.06)。ASA 或他汀类药物联合治疗的使用者抗抑郁药起始风险降低,而 ASA 单药治疗的使用者抗抑郁药起始风险略有增加。相反,ACEI、BB、利尿剂或二甲双胍与抗抑郁药起始风险增加或降低之间没有统计学证据。我们的混合发现表明,一些心血管药物可能与抗抑郁药起始使用风险降低相关,而其他药物可能不相关。然而,由于研究设计的局限性,可能存在偏倚。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/75e6/10073930/09468e38e45d/PRP2-11-e01078-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验